Navigation Links
PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend
Date:11/23/2009

INCLINE VILLAGE, Nev., Nov. 23 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established November 27, 2009 as the ex-dividend date for its $200 million special dividend to stockholders resulting from the securitization transaction completed on November 2, 2009. The dividend will be paid on December 15, 2009 to all stockholders of record on the record date, December 1, 2009. NASDAQ has set the approximate per share amount of the dividend at $1.67 per share of common stock for purposes of the ex-dividend date on November 27, 2009. This approximate per share amount is based on the number of shares of the Company's common stock outstanding on September 30, 2009.

The actual per share amount of the dividend to be paid on December 15, 2009 will depend on the number of shares of the Company's common stock that are outstanding on the record date of December 1, 2009, and will be announced shortly after the record date. Because the holders of the Company's convertible notes have the right to convert into shares of the Company's common stock, and some of these holders may elect to do so prior to or on the record date, it is not possible to calculate the dividend on a per share basis until shortly after the record date.

As of September 30, 2009, the Company had $200 million in principal that remains outstanding under its unsecured 2.75% Convertible Subordinated Notes due August 16, 2023 (the 2023 Notes) and $228 million in principal that remains outstanding under its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes). The 2023 Notes and 2012 Notes are convertible at any time, at the option of the holder, into shares of the Company's common stock. The conversion rate for the 2023 Notes is $7.63 per share and the conversion rate for the 2012 Notes is $10.59 per share.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

The foregoing statements regarding PDL's intentions with respect to the cash special dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995, and actual results could vary materially from the statements made. PDL's ability to pay the special dividend described above is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets, the continued strength of its royalty assets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.

SOURCE PDL BioPharma, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Special Dividend Payment
2. Helix BioPharma to Present at Merriman Curhan Fords Investor Summit 2009 on November 10th
3. Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference
4. PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction
5. PDL BioPharma Reschedules Third Quarter 2009 Financial Results Conference Call for 8:30 a.m. ET on October 28, 2009
6. PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare Conference on November 4, 2009
7. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
8. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
9. Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools
10. United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
11. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016  A platform of orthopedic device technologies ... one step closer to becoming viable options for ... Inc., a start-up company from Philadelphia, ... for these novel absorbable bone fixation and regenerative ... commercial use. The company has leased space within ...
(Date:12/8/2016)... 8, 2016 This report analyzes the worldwide markets ... Based (Humic, Amino, & Fulvic), Extract Based, and Others. The ... Types: Ornamental & Turf, Row Crops, and Others. The report ... , Japan , Europe ... America , and Rest of World. Annual estimates and ...
(Date:12/8/2016)... 8, 2016  Biotheranostics today announced that new ... the Breast Cancer Index (BCI) in identifying which ... most at-risk for disease recurrence and might benefit ... three studies advancing the understanding of the value ... biology and inform decisions related to patient treatment. ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
Breaking Biology Technology:
(Date:12/5/2016)...  The Office of Justice Programs, National Institute ... Enhance or Replace Medico Legal Autopsies?" on NIJ.gov.  ... replacing forensic autopsies with postmortem X-ray computed tomography, ... response to recommendations made by The National Academy ... as a potential component of medicolegal death investigations. ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/22/2016)... PUNE, India , November 22, 2016 According ... (Single-Factor: (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware ... to 2022", published by MarketsandMarkets, the market is expected to grow from ... at a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):